An FDA Decision You Should Know

This is a post from Cyd Notter’s recent newsletter. Check her out at https://cydnotter.com/

 

As someone with a loved one suffering from dementia, I’m disturbed and frustrated after watching today’s video by Dr. Greger.

Perhaps you’ve heard about the latest Alzheimer’s drug called Aduhelm (aducanumab), which is now on the market at the cost of $56K/year (about $1,000/month out of pocket expense).

Trials of this drug on thousands of patients were stopped early and deemed failures. Not only was the drug ineffective at improving cognition, but 35% of those in the trials suffered brain swelling or bleeding within 4 months.

Because of its ineffectiveness and downright dangers, no one on the FDA expert advisory panel voted in favor of this drug. But that didn’t stop the FDA from approving it anyway, which resulted in three committee members resigning in protest.

So because of the FDA’s irresponsible decisions, Biogen (the drug company) now has until 2030 to prove the drug has any benefit. But in the meantime, the drug is on the market and being prescribed. The families of thousands of Alzheimer’s patients are trusting that this useless, harmful drug is “safe and effective” because of the FDA’s Stamp of Approval. Apparently, the doctors are trusting that too.

Watch Dr. Greger’s video here.

This is another example of why it’s crucial nowadays to do your own research when being prescribed a drug or new treatment. We must become our own health advocates and stop blindly trusting Big Pharma’s TV commercials, prescriptions by well-meaning doctors, and now the FDA’s Stamp of Approval. Here are 7 tips to evaluate everything you hear or read.

Dementia is largely lifestyle-related. Do all you can to prevent this dreaded condition by following a plant-based diet and exercising… both of which are proven more effective than any drug could ever be. I’m here to help if you’d like to get started!

Leave a Reply

Your email address will not be published. Required fields are marked *

Share our post on the social media

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on telegram
Telegram
Share on whatsapp
WhatsApp
Share on email
Email

Recent news